Follow Health Care Reform Insider on Twitter
Loading...
You are here:  Home  >  Emerging Healthcare Models  >  Current Article

Harvard Pilgrim bets on value-based drug payments with new deals for Enbrel and Forteo

February 24, 2017 

As high pharmaceutical prices strain budgets of payers and patients alike, Harvard Pilgrim is betting so-called pay-for-performance deals will help lower drug costs and improve patient outcomes. 

http://www.biopharmadive.com/news/harvard-pilgrim-value-based-amgen-eli-lilly/436673/

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>